Risk Factors and Outcome of Chronic Graft-versus-Host Disease after Allogeneic Stem Cell Transplantation—Results from a Single-Center Observational Study

Slides:

Advertisements

Similar presentations

Thrombotic Microangiopathy Associated with Sirolimus Level after Allogeneic Hematopoietic Cell Transplantation with Tacrolimus/Sirolimus-Based Graft-versus-Host.

Advertisements

Mismatch on Glutathione S-Transferase T1 Increases the Risk of Graft-versus-Host Disease and Mortality after Allogeneic Stem Cell Transplantation María.

In Stem Cell Transplantation by Limiting the Morbidity of Graft-versus-Host Disease Tolerance to Myeloablative Conditioning is Improved Nicolas Novitzky,

The Effect of Statin Use at the Time of Autologous Transplant on Response and Survival in Multiple Myeloma Mehdi Hamadani, Erinn Hade, Don M. Benson,

Incidence and Prognostic Value of Eosinophilia in Chronic Graft-versus-Host Disease after Nonmyeloablative Hematopoietic Cell Transplantation Imran Ahmad,

Pharmacokinetics of Ganciclovir after Oral Valganciclovir versus Intravenous Ganciclovir in Allogeneic Stem Cell Transplant Patients with Graft-versus-Host.

Validation of National Institutes of Health Global Scoring System for Chronic Graft- Versus-Host Disease (GVHD) According to Overall and GVHD-Specific.

Prognostic Factors of Chronic Graft-versus-Host Disease Following Allogeneic Peripheral Blood Stem Cell Transplantation: The National Institutes Health.

Peter Hurley, Suma Konety, Qing Cao, Daniel Weisdorf, Anne Blaes

Graft-Versus-Host Disease and Survival after Cord Blood Transplantation for Acute Leukemia: A Comparison of Japanese versus White Populations Yachiyo.

Allogeneic Stem Cell Transplantation for Relapsed or Refractory Lymphoma after Conditioning with BEAM/Fludarabine/TBI Alix O’Meara, Jörg Halter, Dominik.

The Prognostic Value of YKL-40 Concentrations in Nonmyeloablative Conditioning Allogeneic Hematopoietic Cell Transplantation Anne Mette Mørup, Brian.

Impact of Donor Type on Outcome after Allogeneic Hematopoietic Cell Transplantation for Acute Leukemia Scott R. Solomon, Connie A. Sizemore, Xu Zhang,

Late Acute Graft-versus-Host Disease after Allogeneic Hematopoietic Stem Cell Transplantation Aazim K. Omer, Daniel J. Weisdorf, Aleksandr Lazaryan,

Hematopoietic Stem Cell Transplantation after Reduced Intensity Conditioning in Acute Myelogenous Leukemia Patients Older Than 40 Years Cynthia Huisman,

Oral Manifestations Compatible with Chronic Graft-versus-Host Disease in Patients with Fanconi Anemia Laura Grein Cavalcanti, Renata L. Fuentes Araújo,

Sabina Kersting, Leo F. Verdonck

Assessment of the Hematopoietic Cell Transplantation Comorbidity Index in Non- Hodgkin Lymphoma Patients Receiving Reduced-Intensity Allogeneic Hematopoietic.

Absolute Lymphocyte Count on Day 30 Is a Surrogate for Robust Hematopoietic Recovery and Strongly Predicts Outcome after T Cell-Depleted Allogeneic Stem.

Long-Term Follow-Up of Allogeneic Hematopoietic Stem Cell Transplantation for Solid Cancer Brigitta Omazic, Mats Remberger, Lisbeth Barkholt, Gunnar.

A Genetic Modifier of the Gut Microbiome Influences the Risk of Graft-versus-Host Disease and Bacteremia After Hematopoietic Stem Cell Transplantation

Betty T. Tran, Abigail Halperin, Jason W. Chien

Decision Analysis of Peripheral Blood versus Bone Marrow Hematopoietic Stem Cells for Allogeneic Hematopoietic Cell Transplantation Joseph Pidala, Claudio.

Increased Risk of Bone Loss without Fracture Risk in Long-Term Survivors after Allogeneic Stem Cell Transplantation Bipin N. Savani, Theresa Donohue,

Influence of Polymorphism within the Heme Oxygenase-I Promoter on Overall Survival and Transplantation-Related Mortality after Allogeneic Stem Cell Transplantation

Impact of Ocular Chronic Graft-versus-Host Disease on Quality of Life

Brentuximab Vedotin Is Associated with Improved Progression-Free Survival after Allogeneic Transplantation for Hodgkin Lymphoma Robert Chen, Joycelynne.

Haploidentical Transplantation Using T Cell Replete Peripheral Blood Stem Cells and Myeloablative Conditioning in Patients with High-Risk Hematologic.

Cytomegalovirus Infection after Allogeneic Transplantation: Comparison of Cord Blood with Peripheral Blood and Marrow Graft Sources Christopher M. Walker,

Lymphocyte Phenotype during Therapy for Acute Graft-versus-Host Disease: A Brief Report from BMT-CTN 0302 Javier Bolaños-Meade, Juan Wu, Brent R. Logan,

Low Relapse without Excessive Transplant-Related Mortality following Myeloablative Cord Blood Transplantation for Acute Leukemia in Complete Remission:

Impact of Cytogenetics on Outcome of De Novo and Therapy-Related AML and MDS after Allogeneic Transplantation Philippe Armand, Haesook T. Kim, Daniel.

Validation of the Human Activity Profile Questionnaire in Patients after Allogeneic Hematopoietic Stem Cell Transplantation Philipp Yorck Herzberg, Pia.

John Kuruvilla, John D. Shepherd, Heather J. Sutherland, Thomas J

Effect of Conditioning Regimen Intensity on Acute Myeloid Leukemia Outcomes after Umbilical Cord Blood Transplantation Betul Oran, John E. Wagner, Todd.

Reduced-Intensity Conditioning with Fludarabine, Cyclophosphamide, and Rituximab Is Associated with Improved Outcomes Compared with Fludarabine and Busulfan.

Can Only Partial T-Cell Depletion of the Graft before Hematopoietic Stem Cell Transplantation Mitigate Graft-versus-Host Disease While Preserving a Graft-versus-

Incidence, Predisposing Factors, and Outcome of Engraftment Syndrome in Pediatric Allogeneic Stem Cell Transplant Recipients Irene Schmid, Daniel Stachel,

Treatment of Severe Refractory Acute Graft-versus-Host Disease of the Gastrointestinal Tract with Campath-1H Alessandro Busca, Franco Locatelli, Elisabetta.

Graft-versus-Host Disease Induced Graft-versus-Leukemia Effect: Greater Impact on Relapse and Disease-Free Survival after Reduced Intensity Conditioning

Total Body Irradiation–Based Myeloablative Haploidentical Stem Cell Transplantation Is a Safe and Effective Alternative to Unrelated Donor Transplantation.

Sabina Kersting, Ronald J. Hené, Hein A. Koomans, Leo F. Verdonck

Outcome following Reduced-Intensity Allogeneic Stem Cell Transplantation (RIC AlloSCT) for Relapsed and Refractory Mantle Cell Lymphoma (MCL): A Study.

Effect of Body Mass Index on Mortality of Patients with Lymphoma Undergoing Autologous Hematopoietic Cell Transplantation Willis H. Navarro, Fausto R.

Comparison of Tacrolimus and Sirolimus (Tac/Sir) versus Tacrolimus, Sirolimus, and Mini-Methotrexate (Tac/Sir/MTX) as Acute Graft-versus-Host Disease.

Outcomes of Cord Blood Transplantation as Salvage Therapy after Graft Failure or Relapse after Prior Allogeneic Transplantation Rachel B. Salit, Filippo.

Regression Models for Hazard Rates Versus Cumulative Incidence Probabilities in Hematopoietic Cell Transplantation Data Brent R. Logan, Mei-Jie Zhang,

Central Nervous System Complications after Allogeneic Hematopoietic Stem Cell Transplantation: Incidence, Manifestations, and Clinical Significance Deborah.

Nonmyeloablative Stem Cell Transplantation for Myelodysplastic Syndrome or Acute Myeloid Leukemia in Patients 60 Years or Older Vikas Gupta, Andrew Daly,

Chronic Graft-Versus-Host Disease (cGVHD) following Unrelated Donor Hematopoietic Stem Cell Transplantation (HSCT): Higher Response Rate In Recipients.

Peripheral Blood Eosinophilia Has a Favorable Prognostic Impact on Transplant Outcomes after Allogeneic Peripheral Blood Stem Cell Transplantation Dong.

Unrelated Stem Cell Transplantation after a Reduced Intensity Conditioning Regimen Containing High-Dose Thymoglobulin Leads to Controllable Graft-versus-Host.

High Incidence of Severe Acute Graft-Versus-Host Disease with Tacrolimus and Mycophenolate Mofetil in a Large Cohort of Related and Unrelated Allogeneic.

Improved Outcome for Peripheral Blood Stem Cell Transplantation for Advanced Primary Myelodysplastic Syndrome Scott R. Solomon, Bipin N. Savani, Richard.

A Randomized Double-Blind Trial of Hydroxychloroquine for the Prevention of Chronic Graft-versus-Host Disease after Allogeneic Peripheral Blood Stem Cell.

Young Female Donors Do Not Increase the Risk of Graft-versus-Host Disease or Impact Overall Outcomes in Pediatric HLA-Matched Sibling Hematopoietic Stem.

Preengraftment Syndrome after Unrelated Cord Blood Transplant Is a Strong Predictor of Acute and Chronic Graft-versus-Host Disease Haydar Frangoul, Li.

C-Reactive Protein Levels at Diagnosis of Acute Graft-versus-Host Disease Predict Steroid-Refractory Disease, Treatment-Related Mortality, and Overall.

Long-Term Morbidity and Mortality in Children with Chronic Graft-versus-Host Disease Classified by National Institutes of Health Consensus Criteria after.

Low Serum Levels of Total Rabbit-IgG Is Associated with Acute Graft-Versus-Host Disease after Unrelated Donor Hematopoietic Stem Cell Transplantation:

Mammen Chandy Biology of Blood and Marrow Transplantation

Recipient Immune Modulation with Atorvastatin for Acute Graft-versus-Host Disease Prophylaxis after Allogeneic Transplantation Abraham S. Kanate, Parameswaran.

Incidence and Outcome of Chronic Graft-versus-Host Disease Using National Institutes of Health Consensus Criteria Madan Jagasia, Jennifer Giglia, Wichai.

Prospective Monitoring of Tumor Necrosis Factor α and Interferon γ to Predict the Onset of Acute and Chronic Graft-versus-Host Disease after Allogeneic.

Adult Recipients of Matched Related Donor Blood Cell Transplants Given Myeloablative Regimens Including Pretransplant Antithymocyte Globulin Have Lower.

Outcomes among Patients with Recurrent High-Risk Hematologic Malignancies after Allogeneic Hematopoietic Cell Transplantation Marco Mielcarek, Barry.

Cannabidiol for the Prevention of Graft-versus-Host-Disease after Allogeneic Hematopoietic Cell Transplantation: Results of a Phase II Study Moshe Yeshurun,

Mary Eapen Biology of Blood and Marrow Transplantation

Futility of Relapsed Diffuse Large B Cell Lymphoma Transplantation?

Daniel Couriel, Chitra Hosing, Rima Saliba, Elizabeth J

Presentation transcript:

Risk Factors and Outcome of Chronic Graft-versus-Host Disease after Allogeneic Stem Cell Transplantation—Results from a Single-Center Observational Study Matthias Grube, Ernst Holler, Daniela Weber, Barbara Holler, Wolfgang Herr, Daniel Wolff Biology of Blood and Marrow Transplantation Volume 22, Issue 10, Pages 1781-1791 (October 2016) DOI: 10.1016/j.bbmt.2016.06.020 Copyright © 2016 The American Society for Blood and Marrow Transplantation Terms and Conditions

Figure 1 Maximum severity of cGVHD according to organ manifestation. Biology of Blood and Marrow Transplantation 2016 22, 1781-1791DOI: (10.1016/j.bbmt.2016.06.020) Copyright © 2016 The American Society for Blood and Marrow Transplantation Terms and Conditions

Figure 2 (A) Cumulative incidence of TRM in relation to the presence of cGVHD. Cumulative incidence of TRM between patients without (n = 147) and with (n = 243) cGVHD was calculated by the Kaplan-Meier method. (B) Cumulative incidence of TRM in relation to the onset type of cGVHD. Cumulative incidence of TRM between patients with de novo (n = 76), quiescent (n = 156), and progressive (n = 11) onset of cGVHD was calculated by the Kaplan-Meier method. (C) Cumulative incidence of TRM in relation to the platelet count at the time of cGVHD onset. Cumulative incidence of TRM between patients with platelets of more than 100/nL (n = 165) and less (n = 78) than 100/nL at the time of GVHD onset was calculated by the Kaplan-Meier method. (D) Cumulative incidence of TRM in relation to grade of severity of cGVHD. Cumulative incidence of TRM between patients without (n = 147) and with mild (n = 62), moderate (n = 85), or severe (n = 96) cGVHD was calculated by the Kaplan-Meier method. (E) Cumulative incidence of TRM in relation to organ involvement of severe cGVHD. Cumulative incidence of TRM between patients without cGVHD (n = 147) and patients with severe cGVHD with (n = 59) or without (n = 37) lung, liver, or gastrointestinal (GI) tract involvement (lung/liver/GI) was calculated by the Kaplan-Meier method. Biology of Blood and Marrow Transplantation 2016 22, 1781-1791DOI: (10.1016/j.bbmt.2016.06.020) Copyright © 2016 The American Society for Blood and Marrow Transplantation Terms and Conditions

Figure 3 (A) Cumulative incidence of relapse in relation to the grade of cGVHD. Cumulative incidence of relapse between patients without (n = 147) and with mild (n = 62), moderate (n = 85), or severe (n = 96) cGVHD was calculated by the Kaplan-Meier method. (B) Cumulative incidence of relapse in relation to organ involvement of severe cGVHD. Cumulative incidence of relapse between patients without cGVHD (n = 147) and patients with severe cGVHD with (n = 59) or without (n = 37) lung, liver, or gastrointestinal (GI) tract involvement was calculated by the Kaplan-Meier method. Biology of Blood and Marrow Transplantation 2016 22, 1781-1791DOI: (10.1016/j.bbmt.2016.06.020) Copyright © 2016 The American Society for Blood and Marrow Transplantation Terms and Conditions

Figure 4 (A) Overall survival in relation to the onset type of cGVHD. Overall survival between patients with de novo (n = 76), quiescent (n = 156), and progressive (n = 11) onset of cGVHD was calculated by the Kaplan-Meier method. (B) Overall survival in relation to the platelet count at the time of cGVHD onset. Overall survival between patients with platelets of more than 100/nL (n = 165) and less (n = 78) than 100/nL at the time of GVHD onset was calculated by the Kaplan-Meier method. (C) Overall survival in relation to the grade of cGVHD. Overall survival between patients without (n = 147) and with mild (n = 62), moderate (n = 85), or severe (n = 96) cGVHD was calculated by the Kaplan-Meier method. (D) Overall survival in relation to organ involvement of severe cGVHD. Overall survival between patients without cGVHD (n = 147) and patients with severe cGVHD with (n = 59) or without (n = 37) lung, liver, or gastrointestinal (GI) tract involvement was calculated by the Kaplan-Meier method. Biology of Blood and Marrow Transplantation 2016 22, 1781-1791DOI: (10.1016/j.bbmt.2016.06.020) Copyright © 2016 The American Society for Blood and Marrow Transplantation Terms and Conditions